Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses GLUE in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named GLUE in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Markus Warmuth | $650,000 | $0 | $910,080 | $3,043,648 | $429,000 | $0 | $0 | $5,032,728 |
| President and Chief Executive Officer | ||||||||
| Philip Nickson | 520,000 | 0 | 255,960 | 852,221 | 299,600 | 0 | 14,000 | 1,941,781 |
| Chief Business and Legal Officer | ||||||||
| Filip Janku | 520,000 | 0 | 255,960 | 852,221 | 299,600 | 0 | 14,000 | 1,941,781 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Markus Warmuth | $5,032,728 | $2,440,811 | — | +2,591,917 |
| Philip Nickson | 1,941,781 | 1,287,628 | — | +654,153 |
| Filip Janku | 1,941,781 | 1,257,869 | — | +683,912 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Philip Nickson | Option | 4,413 | 13.41 | — |
| Filip Janku | Option | 36,563 | 7.78 | — |
| Philip Nickson | Option | 56,771 | 5.71 | — |
| Markus Warmuth | RSU | 128,000 | — | 2,007,040 |
| Filip Janku | RSU | 36,000 | — | 564,480 |
| Philip Nickson | RSU | 36,000 | — | 564,480 |
| Markus Warmuth | Option | 19,725 | 13.41 | — |
| Markus Warmuth | Option | 127,834 | 7.78 | — |
| Markus Warmuth | Option | 180,209 | 5.71 | — |
| Markus Warmuth | Option | 575,000 | 7.11 | — |
| Filip Janku | Option | 5,407 | 13.41 | — |
| Filip Janku | Option | 30,000 | 7.35 | — |
| Filip Janku | Option | 63,021 | 5.71 | — |
| Filip Janku | Option | 161,000 | 7.11 | — |
| Philip Nickson | Option | 33,489 | 7.78 | — |
| Philip Nickson | Option | 24,167 | 3.98 | — |
| Philip Nickson | Option | 161,000 | 7.11 | — |
The company aims to align the interests of named executive officers with those of stockholders and motivate contributions to performance. Compensation is set based on market-competitive levels, individual performance, and a long-term commitment to the company, with a goal of ensuring compensation is competitive and fair.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Radford, an Aon Hewitt Company |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Andrew Schiff, M.DIndependent · Board Chair · Audit | $79,167 | — | $107,686 | — | — | $186,853 |
| Kimberly L. Blackwell, M.DIndependent · Compensation (Chair) | 55,000 | — | 107,686 | — | — | 162,686 |
| Christine SiuIndependent · Audit (Chair) | 55,000 | — | 107,686 | — | — | 162,686 |
| Anthony Manning, Ph.DIndependent · Compensation · Nominating and Corporate Governance | 52,083 | — | 107,686 | — | — | 159,769 |
| Jan Skvarka, Ph.D, MBAIndependent · Nominating and Corporate Governance (Chair) | 49,167 | — | 107,686 | — | — | 156,853 |
| Ali Behbahani, M.DIndependent · Compensation | 47,500 | — | 107,686 | — | — | 155,186 |
| Eric Hughes, M.D., Ph.DIndependent · Nominating and Corporate Governance | 42,917 | — | 107,686 | — | — | 150,603 |
| Anthony ManningIndependent | 52,083 | — | — | — | — | 52,083 |
| Markus Warmuth, M.DEmployee director | — | — | — | — | — | 0 |
| Chandra P. Leo, M.DIndependent · Audit | 0 | — | 0 | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $432,917 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $432,917 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Monte Rosa Therapeutics | 2025 | Markus Warmuth | $650,000 | $910,080 | $3,043,648 | $429,000 | $5,032,728 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Markus Warmuth | DEF 14A | 2026-04-29 | 0001193125-26-191439 | Section “Executive Compensation”. As printed: 5,032,728. Filing ↗machine: r2 · c25 · span 420815–420824 |
| 2 | Section 01, Philip Nickson | DEF 14A | 2026-04-29 | 0001193125-26-191439 | Section “Executive Compensation”. As printed: 1,941,781. Filing ↗machine: r6 · c25 · span 460643–460652 |
| 3 | Section 01, Filip Janku | DEF 14A | 2026-04-29 | 0001193125-26-191439 | Section “Executive Compensation”. As printed: 1,941,781. Filing ↗machine: r4 · c25 · span 440734–440743 |
| 4 | Section 08, Andrew Schiff, M.D | DEF 14A | 2026-04-29 | 0001193125-26-191439 | Section “Director Compensation”. As printed: 186,853. Filing ↗ |
| 5 | Section 08, Kimberly L. Blackwell, M.D | DEF 14A | 2026-04-29 | 0001193125-26-191439 | Section “Director Compensation”. As printed: 162,686. Filing ↗ |
| 6 | Section 08, Christine Siu | DEF 14A | 2026-04-29 | 0001193125-26-191439 | Section “Director Compensation”. As printed: 162,686. Filing ↗ |
| 7 | Section 08, Anthony Manning, Ph.D | DEF 14A | 2026-04-29 | 0001193125-26-191439 | Section “Director Compensation”. As printed: 159,769. Filing ↗ |
| 8 | Section 08, Jan Skvarka, Ph.D, MBA | DEF 14A | 2026-04-29 | 0001193125-26-191439 | Section “Director Compensation”. As printed: 156,853. Filing ↗ |
| 9 | Section 08, Ali Behbahani, M.D | DEF 14A | 2026-04-29 | 0001193125-26-191439 | Section “Director Compensation”. As printed: 155,186. Filing ↗ |
| 10 | Section 08, Eric Hughes, M.D., Ph.D | DEF 14A | 2026-04-29 | 0001193125-26-191439 | Section “Director Compensation”. As printed: 150,603. Filing ↗ |
| 11 | Section 08, Anthony Manning | DEF 14A | 2026-04-29 | 0001193125-26-191439 | Section “Director Compensation”. As printed: 52,083. Filing ↗ |
| 12 | Section 08, Markus Warmuth, M.D | DEF 14A | 2026-04-29 | 0001193125-26-191439 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 13 | Section 08, Chandra P. Leo, M.D | DEF 14A | 2026-04-29 | 0001193125-26-191439 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 14 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 15 | Section 09b board cost (computed) | Computed | — | computed | Cash 432,917 + equity 0 + all other 0 = 432,917, summed across the director compensation table rows.machine: formula: Σ = 432,917 |
| 16 | Monte Rosa Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191439 | CEO total compensation as printed in Monte Rosa Therapeutics's own proxy. As printed: 5,032,728. Filing ↗machine: r2 · c25 · span 420815–420824 |